Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) reported preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and a year-to-date gross margin of about 35%. The company increased its full-year 2026 AUCATZYL sales guidance to $140–$150 million, up from prior guidance of $120–$135 million.
Autolus highlighted that Q2 2026 AUCATZYL sales grew about 70% versus Q1 2026 and more than 100% versus Q2 2025, supported by higher utilization at existing treatment centers and new centers coming online. Gross margin improved from roughly -20% in the second half of 2025 to about 35% in the first half of 2026.
The company also entered a five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors. An initial $75 million tranche closed on July 30, 2026, with an additional $25 million available for up to six months and up to $150 million more contingent on revenue milestones. The facility bears interest at one-month SOFR (with a 3.50% floor) plus 7.25%. Autolus issued Perceptive a warrant to purchase up to 3.5 million ADSs at $1.9314 per ADS. The first two tranches, totaling $100 million, together with existing cash, are expected to fund operations into Q2 2028.
Positive
- Preliminary Q2 2026 AUCATZYL revenue approximately $45 million
- FY 2026 AUCATZYL sales guidance raised to $140–$150 million from $120–$135 million
- AUCATZYL sales growth about +70% vs Q1 2026 and >100% vs Q2 2025
- Gross margin improvement from roughly -20% in H2 2025 to about 35% in H1 2026
- Credit facility capacity up to $250 million over five years
- Runway first $100 million plus cash expected to fund into Q2 2028
Negative
- Debt cost interest set at one-month SOFR (min 3.50%) plus 7.25% per annum
- Potential dilution from warrant to purchase up to 3.5 million ADSs at $1.9314
Market Reaction – AUTL
Following this news, AUTL has gained 11.43%, reflecting a significant positive market reaction. Our momentum scanner has triggered 14 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $1.66.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 01 | Inducement grants | Neutral | +0.0% | Equity awards granted to 13 new employees under the inducement plan |
| Jun 25 | Investor conference | Neutral | +0.0% | Company announced participation in the H.C. Wainwright virtual conference |
| Jun 12 | Biotechnology award | Positive | +0.0% | Company received the 2026 Prix Galien UK Award for Best Biotechnology Product |
| May 27 | Investor conferences | Neutral | +0.0% | Company announced participation in two investor conferences in early June |
| May 21 | Clinical data update | Positive | +3.0% | ASCO update reported remission and response-duration data from the FELIX study |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions were mostly flat, with the only positive move occurring after a clinical-data update.
Key Terms
senior credit facility financial
SOFR financial
interest-only financial
VWAP financial
lymphoblastic leukemia medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately
$45 million and gross margin of approximately35% year-to-date - FY 2026 sales guidance increased to
$140 –$150 million , from$120 –$135 million - Capital base strengthened through five-year, interest-only credit facility with
$75 million funded at close - Autolus to report Q2 2026 financial results on August 11, 2026
LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced preliminary second quarter 2026 AUCATZYL net product revenue of approximately
“In the second quarter, AUCATZYL sales increased approximately
“The strategic financing with Perceptive Advisors provides us with additional capital to support key inflection points for the business, including clinical data milestones in our oncology and autoimmune development programs, and is underpinned by the positive sales and gross margin development from our core adult lymphoblastic leukemia (ALL) commercial business,” said Rob Dolski, Chief Financial Officer of Autolus. “With obe-cel’s unique profile we have a meaningful opportunity to expand into new and larger markets which we view as significant growth drivers. The potential additional tranches in this financing, if drawn down, provide optionality and flexibility to invest in these larger autoimmune indications.”
“Our goal is to support technologies that carry a meaningful opportunity to help patients, and we are pleased to partner with Autolus in their mission to deliver obe-cel to people with cancer and autoimmune diseases. With this facility, we are providing flexible growth capital to enable the Company to deliver on its strategic priorities and catalyze value creation,” said Sam Chawla, Portfolio Manager at Perceptive Advisors. “This financing reflects our confidence in the leadership team at Autolus to continue to deliver on obe-cel’s commercial and development plans.”
The Credit Facility will bear interest at a rate per annum equal to the one month secured overnight financing rate (“SOFR”) (subject to a SOFR floor of
The combined first and second tranches from the Credit Facility, totaling
Autolus will report full second quarter 2026 financial results on August 11, 2026. Further information on the terms of the credit facility can be found in the Company’s filings with the U.S. Securities and Exchange Commission in connection with the Credit Facility.
Jefferies International Limited acted as debt advisor and Cooley served as legal advisor to Autolus Therapeutics in connection with the Credit Facility. Latham & Watkins served as legal advisor to Perceptive.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus’ future expectations, plans and prospects, including guidance on 2026 AUCATZYL net product revenue and improvement in gross margin, and the impact of recently announced restructuring activities; the impact of the Credit Facility on Autolus’ anticipated cash runway; Autolus’s ability to achieve the milestones under the Credit Facility, including with respect to the availability of the remaining tranches of the Credit Facility and interest margin reductions; the therapeutic potential and expected clinical benefits of AUCATZYL for adult patients with r/r B-ALL and obe-cel in additional indications including LN and progressive MS; Autolus’s ability to obtain and maintain regulatory approval for obe-cel for adult r/r B-ALL in additional territories and the timing thereof; expectations regarding the commercialization, marketing and manufacturing of AUCATZYL for adult r/r B-ALL, including expanding into additional territories and the related timing of reaching patients in such territories; the development of obe-cel in autoimmune indications and of additional product candidates, including statements regarding the initiation, timing, progress and the results of clinical studies or trials and related preparatory work; the period during which the results of clinical studies or trials will become available; Autolus’ plans to expand, develop and enhance its manufacturing activities; and Autolus’ pursuit of expanded market access across Europe. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks identified in the section titled "Risk Factors" in Autolus' Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC), on March 27, 2026 and any of its subsequent Quarterly Reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the SEC. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing Autolus’ views as of any date subsequent to the date of this press release.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
